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In the last week paper in Science Transl Med, Francis 
Collins,  Dimitri  Krainc,  Kan  Cao  and  co-workers 
described that rapamycin reverses cellular phenotypes 
in Hutchinson-Gilford progeria syndrome (HGPS) cells 
[1]. Is it a co-incidence that rapamycin also suppresses 
senescence  in  regular  (non-HGPS)  mammalian  cells 
[2]? 
 
Clearance of progerin by rapamycin 
 
Hutchinson–Gilford  progeria  syndrome  (HGPS)  is  a 
rare  genetic  disorder  characterized  by  some  features 
reminiscent  of  aging,  including  atherosclerosis  and 
alopecia [3-6]. The median life span is 13 years, and the 
main cause of death is myocardial infarction and stroke. 
Progeria  is  mainly  caused  by  the  abnormal 
accumulation of progerin, a mutant form of the nuclear 
envelope  component  lamin  A  [7,  8].  In  cell  culture, 
HGPS cells are prone to replicative senescence (Figure 
1)  [9-12].  Accumulation  of  progerin  causes  nuclear 
abnormalities,  mitotic  abnormalities  and  accelerate 
telomere  shortening.  This  causes  DNA  damage 
response, p53 induction and cell cycle arrest [11, 13-
16]. After a number of cell divisions in culture, cells 
stop proliferating (replicative senescence). 
 
Very  recently  Cao  et  al  described  that  rapamycin 
stimulates clearance of progerin and therefore prevents 
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nuclear abnormalities and delays replicative senescence 
[1].  Rapamycin  eliminates  the  cause  of  the 
abnormalities  and  therefore  is  expected  to  be  an 
effective treatment in progeria [1]. In addition to this 
strong rationale [1], there is one additional indication 
for rapamycin, regardless of progerin clearance, namely 
suppression  of  geroconversion  (conversion  from 
quiescence to senescence) by rapamycin [2,17-19]. 
 
 
 
 
 
 
Prevention of geroconversion by rapamycin 
 
Normal human cells undergo replicative senescence due 
to telomere shortening, which causes cell cycle arrest 
[9, 20-22]. But cell cycle arrest is not yet senescence 
[23, 19]. In the young organism, post-mitotic cells are 
not senescent.  Such cells must undergo geroconversion 
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Figure  1.  Progerin-induced  replicative  limit  in  progeric  cells 
Rapamycin  decreases  levels  of  progerin  and  thus  prevents 
telomere erosion and cell cycle arrest during  lifespan.  In  cell  culture,  senescence  is 
characterized  by  large  flat  cell  morphology 
(hypertrophy),  beta-Gal  staining,  hyper-secretory 
phenotype,  activated  DNA-damage  response  (even  in 
the  absence  of  DNA  damage),  resistance  to  signals 
(such  as  insulin),  elevated  cyclins  with  inappropriate 
drive  into  S-phase,  and  loss  of  proliferative  potential 
(PP) [17, 24-42, 17]. Loss of PP, a convenient marker in 
cell  culture,  means  that  the  cells  cannot  resume 
proliferation even when they are released from arrest, 
for example, by switching p21 off  [2, 43]. Senescent 
phenotype (including loss of PP) can be linked to hyper-
active growth-promoting and nutrient-sensing pathways 
such as mTOR (Target of Rapamycin). In proliferating 
cells, growth factors (and nutrients) activate cell mass 
growth, which is balanced by division. When the cell 
cycle  is  arrested,  then  activated  mTOR  drives  the 
senescent  morphology  [2,  17].  Over-activation  of  the 
mTOR pathway causes hyper-activation and exhaustion 
of stem cells too [44- 46]. 
 
In replicative senescence of normal human (not rodent) 
cells,  telomere  erosion  during  20-70  division  cycles 
causes DDR and cell cycle arrest. Telomere erosion is a 
very peculiar (and time consuming) method to achieve 
cell cycle arrest. One can accelerate the process. Cell 
cycle can be directly arrested by DNA damaging drugs, 
expression  of  p53,  p21,  p16  or  of  constantly  hyper-
activated Ras/Rak/Akt [47-50]. When the cell cycle is 
arrested  but  mTOR  is  active  then  cells  senesce  [17]. 
Hyper-active Ras, Raf, Akt not only can arrest cycle but 
additionally  activate  the  mTOR  pathway.  Rapamycin 
and  also  upstream  inhibitors  of  mTOR  suppresses 
geroconversion  in  different  models  of  premature  and 
physiological senescence in culture [2, 17, 42, 51-55]. 
 
By causing cell cycle arrest, p53 puts such cells on the 
path  of  senescence.  Simultaneously,  p53  can  inhibit 
mTOR  [56-60]  and  can  suppress  geroconversion  [61-
66, 58]. This may determine a dual role of p53 in aging 
[63, 67-70]. 
 
mTOR stimulates cellular growth and functions [71-74] 
and cause signal (insulin) resistance by feedback loops 
[75-  82].  Aging  cells  are  over-activated,  hyper-
functional (for example, hyper-secretory) and secondary 
signal  resistant  [18].  This  may  result  in  cell 
malfunctions and even cellular loss (for example, loss 
of  beta-cells  in  diabetes  type  II).  Hyper-functions, 
malfunctions  and  signal-resistance  in  turn  cause  age-
related  diseases  from  metabolic  syndrome, 
atherosclerosis  and  hypertension  to  neurodegeneration 
and  osteroporosis    [83-85].  And  not  coincidentally, 
rapamycin is indicated for prevention of all age-related 
diseases  including  cancer  [83-86].  The  sum  of  all 
diseases determines the risk of death [85]. And aging is 
defined as increase of accidence of death with age. So if 
TOR-dependent  cellular  aging  increases  the  risk  of 
death, then rapamycin must extend life span.  Indeed, 
inhibition of the TOR pathway extends lifespan in span 
in diverse organisms from yeast to mice [87-97, 46]. 
 
 
 
 
 
Linking progeria to aging: 4 scenarios 
 
There are at least four models, which are not mutually 
exclusive 
 
Scenario 1. Progerin is detectable in normal cells from 
normal  elderly  humans  [98].  In  normal  human 
fibroblasts,  telomere  damage  during  replicative 
senescence  activates  progerin  production  [10].  In 
theory,  progerin  can  accumulate.  In  this  scenario, 
normal aging is caused by progerin or at least in some 
individuals accumulation of progerin is life-limiting. If 
so,  progeria  is  a  truly  accelerated  aging  or  at  least 
accelerated  component  of  aging.    Still,  there  is  no 
evidence  so  far  that  progerin  normally  reaches  toxic 
levels.  Also  telomere  erosion  is  preferentially  a  cell 
culture phenomenon. And elevated progerin production 
was not seen during cellular senescence that does not 
entail  telomere  shortening  [10].  On  the  other  hand, 
patients with dyskeratosis congenita, an inherited bone 
marrow  failure  syndrome,  have  very  short  telomeres 
[99].  Also,  there  may  be  synergy  with  additional 
abnormalities  such  as  abnormalities  of  nuclear  pore 
complex in aging cells [100]. 
 
Scenario 2. Normal aging is caused by overactivation of 
TOR-centric  pathways  such  as  mTOR,  MAPK  and 
kinases of the DNA damage response (DDR).  Progerin 
can activate DDR  [101]. In turn, DDR may activate the 
mTOR pathway  [102]. Noteworthy, cellular senescence 
of  regular  cells  is  characterized  by  DDR  even  in  the 
absence of actual DNA damage (pseudo-DDR) [103]. 
And pseudo-DDR is inhibited by rapamycin [103]. So 
there is cross talk between mTOR and DDR [104, 105]. 
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Figure  2.  mTOR-driven  senescence  in  arrested  normal  cells 
When cell cycle is blocked, mTOR drives senescence Therefore, by activating DDR pathways, progerin might 
also promote geroconversion. 
 
Scenario 3.   mTOR inhibits autophagy and  insufficient 
autophagy  is  involved  in  normal  aging  [106-109]. 
Rapamycin also causes clearance of aggregation-prone 
proteins  [110].  In  progeria,  rapamycin  activates 
clearance of progerin thus slowing down the progeric 
aging.  Thus,  rapamycin  can  affect  both  progeria  and 
normal aging via activation of autophagy of different 
proteins and structures. 
 
Scenario  4.  Two  different  mTOR  activities  are 
responsible  for  deceleration  of  normal  and  progeric 
aging. In progeria, this is autophagy. In normal aging, 
this is suppression of cellular hyper-functions, such as 
hyperfunctions  (such  as  secretion)  and  hormone-
resistance.  Rapamycin  would  be  effective  in  both 
conditions  but  by  different  reasons.  In  analogy, 
rapamycin  could  be  used  for  certain  fungal  and  viral 
infection, even though they do not cause normal aging. 
 
Accelerated  aging 
 
Still, progeria is not accelerated “normal” aging exactly. 
What  is  accelerated  “normal”  aging  or  accelerated 
aging, for brevity. If aging is driven by inappropriate 
activation of nutrient-, hormone- and mitogen-sensing 
pathways such as mTOR, then nutrients and insulin can 
accelerate aging. In fact, obesity is associated with all 
age-related diseases and dramatically shortens life span. 
This is the accelerated normal aging. As an example, 
the  maximum  “years  lost  life”  (YLL)  for  white  men 
aged 20 to 30 years with a severe level of obesity (BMI 
>45)  is  13  years,  representing  a  22%  reduction  in 
expected  remaining  life  span  [111].  As  long  ago 
suggested  by  the  Russian  endocrinologist  Vladimir 
Dilman, time flies faster in the obese. 
 
This also could be considered from the point of view of 
a quasi-programmed aging. Aging is not programmed of 
course but is an aimless continuation of a program of 
developmental  growth  [74,  112-115].  And  growth  is 
driven in part by mTOR (activated by growth factors 
and nutrients). 
 
Rapamycin for progeria and (age-related diseases) 
 
Inhibiting  farnesylation  of  progerin  by  farnesyl 
transferase  inhibitors  (FTI)  prevents  the  nuclear 
blebbing of progeria and has positive effects in animal 
models [116-122]. Yet, the FTI lonafarnib is a relatively 
cytotoxic agent with gastrointestinal and hematological 
dose-limiting toxicities (in cancer patients) [123]. It was 
shown  that  insulin-like  growth  factor  1  extends 
longevity in a mouse model of human premature aging 
[124].  However,  there  is  still  a  long  way  to  clinical 
applications. 
 
Therefore, rapamycin, a non-toxic prescription drug, is 
a very attractive option. Also, in addition to clearance of 
progerin,  rapamycin  in  theory  would  suppress 
geroconversion  downstream  of  progerin.  Furthermore, 
rapamycin prevents atherosclerosis in animal models of 
accelerated atherosclerosis [125, 126] and can prevent 
atherosclerotic  restenosis  in  humans    [127].  And 
accelerated atherosclerosis is one of the main symptoms 
of progeria and ultimately the cause of death. 
 
There  is  a  misconception  that  rapamycin  increases 
chances of infections and cancer. In reality, rapamycin 
is an effective cancer preventive agent in both animals 
[128, 96, 129] and humans [130, 131], in part, because 
it  slows  down  organismal  aging  [132].  Rapamycin  is 
not a general immunosuppressant, it induces tolerance 
to transplanted organs (when used in combination with 
immunosuppressants).    “Figuratively,  it  transforms 
immunity  from  aged-type  to  infant-type”  [83]. 
Rapamycin can actually improve responses to infections 
as  immunostimulator  [133,  46,  134].  Furthermore,  to 
treat progeria (as well as age-related diseases in normal 
aging),  rapamycin  will  be  used  in  lower  doses  and 
intermittently, so a few (if any) side effects could be 
expected. 
 
As discussed [135], an increase of lipids in blood occurs 
because rapamycin increases lyposysis (like starvation) 
and  simultaneously  decreases  lipid  entry  into  the 
tissues,  including  the  arterial  wall.  Therefore, 
rapamycin  prevents  atherosclerosis  in  animals  and 
humans (despite increased lipids) [125-127]. Needless 
to  say,  rapamycin  is  a  clinically  approved,  non-toxic 
drug, which is used for many years in high and chronic 
doses in transplant patients. But what is about treating 
children?  Rapamycin  is  successfully  used  for  the 
treatment of TSC syndrome in children [136].  Now is a 
turn of progeria [1]. And perhaps now is the time for 
postponing age-related diseases of normal aging in our 
life time [137]. 
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